<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Effect of antidepressants on suicide risk in adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Effect of antidepressants on suicide risk in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Effect of antidepressants on suicide risk in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">A John Rush, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter P Roy-Byrne, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David Solomon, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 21, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H15733973"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Antidepressants are efficacious for treating depressed patients, especially patients who are severely ill and may be at greater risk for suicide [<a href="#rid1">1-3</a>]. However, all antidepressants in the United States carry a warning that they are associated with an increased risk of suicidality in adults age 18 to 24 years during initial treatment (generally the first one to two months) [<a href="#rid4">4</a>]. Suicidality includes suicidal ideation, action to prepare for an attempt, attempt or nonfatal self-harm, or death. The warning also applies to children and adolescents.</p><p>This topic reviews whether antidepressants affect the risk of suicidality in adults. The effect of antidepressants on suicide risk in children and adolescents, risk factors and management of suicidality in adults, and the pharmacology and use of antidepressants to treat depression are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1225.html" rel="external">"Effect of antidepressants on suicide risk in children and adolescents"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1708.html" rel="external">"Suicidal ideation and behavior in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1713.html" rel="external">"Serotonin-norepinephrine reuptake inhibitors: Pharmacology, administration, and side effects"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1717.html" rel="external">"Tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1715.html" rel="external">"Monoamine oxidase inhibitors (MAOIs): Pharmacology, administration, safety, and side effects"</a>.)</p><p></p><p class="headingAnchor" id="H16005408"><span class="h1">BACKGROUND</span><span class="headingEndMark"> — </span>In 1990, concerns were first raised about antidepressants precipitating suicidality (ie, suicidal ideation, action to prepare for an attempt, attempt or nonfatal self-harm, or death). At that time, case reports described patients who developed intense suicidal ideation during treatment with <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a>, a selective serotonin reuptake inhibitor [<a href="#rid5">5</a>]. The manufacturer of fluoxetine subsequently performed a meta-analysis of 17 randomized trials (3065 patients with major depression) and found that the pooled incidence of the combined outcome of preparatory acts, nonfatal self-harm, or death did not differ significantly between patients who received fluoxetine or placebo (0.3 versus 0.2 percent) [<a href="#rid6">6</a>]. In addition, baseline suicidal ideation improved significantly more with fluoxetine than placebo (72 versus 55 percent).</p><p>Concerns about antidepressants and suicidality reemerged in 2003 when the US Food and Drug Administration (FDA) issued an advisory in response to numerous reports of suicidal ideation, suicide attempts, and suicide deaths in clinical trials of antidepressants in pediatric patients with unipolar major depression [<a href="#rid4">4,7</a>]. In 2004, the FDA reexamined data from pediatric randomized trials of the antidepressant drugs <a class="drug drug_general" data-topicid="9171" href="/d/drug information/9171.html" rel="external">bupropion</a>, <a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">citalopram</a>, <a class="drug drug_general" data-topicid="9046" href="/d/drug information/9046.html" rel="external">escitalopram</a>, <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a>, <a class="drug drug_general" data-topicid="8474" href="/d/drug information/8474.html" rel="external">fluvoxamine</a>, <a class="drug drug_general" data-topicid="9656" href="/d/drug information/9656.html" rel="external">mirtazapine</a>, <a class="drug drug_general" data-topicid="9684" href="/d/drug information/9684.html" rel="external">nefazodone</a>, <a class="drug drug_general" data-topicid="9743" href="/d/drug information/9743.html" rel="external">paroxetine</a>, <a class="drug drug_general" data-topicid="9886" href="/d/drug information/9886.html" rel="external">sertraline</a>, and <a class="drug drug_general" data-topicid="10042" href="/d/drug information/10042.html" rel="external">venlafaxine</a>. The analyses suggested an increased risk of suicidal ideation, preparatory acts for self-harm, or nonfatal self-harm occurring during the first weeks of treatment with an antidepressant, compared with placebo. As a result, the FDA elevated the advisory and issued a warning regarding emergence of suicidality in children and adolescents starting antidepressant treatment [<a href="#rid4">4,8</a>].</p><p>The FDA issued an advisory in 2005 about suicidality in adults treated with antidepressant drugs [<a href="#rid4">4</a>]. In 2007, the FDA extended the 2004 warning about antidepressant drugs and suicidality to include adults age 18 to 24 years and all antidepressant drugs. The warning issued in 2007 did not advise against the prescription of antidepressants for approved indications, including depressive and anxiety disorders. Instead, the warning emphasized that:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients 18 to 24 years of age should be informed about the risk of developing suicidality during initial antidepressant treatment (generally the first one to two months).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Clinicians should monitor patients closely during initial antidepressant treatment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Depression and certain other serious psychiatric disorders are themselves associated with an increased risk of suicidality.</p><p></p><p>Although the risk of suicidality posed by antidepressants remains in question, there is no doubt about the risk of suicidality in untreated depressed patients [<a href="#rid9">9</a>]. As an example, an observational study of 186 depressed patients followed for up to 38 years found that 14 percent committed suicide, which was 27 times greater than the rate in the general population; treatment with an antidepressant was associated with a lower rate of suicide mortality. [<a href="#rid10">10</a>].</p><p>There is no evidence that more frequent contact between clinicians and depressed patients reduces the risk of suicide attempt or suicide death. However, there is evidence that fewer symptoms of depression occur in patients who receive follow-up care, compared with patients who do not [<a href="#rid11">11</a>]. Advisories and warnings about the need for more frequent monitoring do not seem to have increased the low rate of follow-up care during antidepressant treatment [<a href="#rid12">12</a>].</p><p class="headingAnchor" id="H16005416"><span class="h1">EVIDENCE REVIEW</span></p><p class="headingAnchor" id="H3507850746"><span class="h2">Overview</span><span class="headingEndMark"> — </span>There is no clear evidence that treatment of depressed patients with antidepressant drugs increases the average risk of suicidality (ie, suicidal ideation, action to prepare for an attempt, attempt or nonfatal self-harm, or death) [<a href="#rid9">9,13</a>]. However, there may be an age-specific effect, such that antidepressants may raise the risk of suicide attempts (nonfatal self-harm) or preparatory acts in patients age 18 to 24 years during the first several weeks of treatment, yet have no effect upon patients age 25 to 30 years, and may lower the risk in patients 31 years and older. It is not known whether there are other sociodemographic or clinical factors associated with risk of suicidality in patients treated with antidepressants. In addition, it is not known whether specific antidepressant drugs differ in their risk of suicidality, or how polypharmacy affects the risk.</p><p>Several methodologic issues make it difficult to answer the question of whether antidepressants cause suicidality. The associations between depression and use of antidepressants and between depression and suicidality potentially confound the results of studies that examine the association between antidepressants and suicidality [<a href="#rid14">14</a>]. Another issue is the reliability of classifying certain events or behavior as suicide attempts [<a href="#rid15">15</a>]. (See <a class="local">'Methodologic issues'</a> below.)</p><p>Three types of studies have examined the association between antidepressants and suicidality. In order of quality, these are [<a href="#rid16">16</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Randomized trials (including meta-analyses)</p><p class="bulletIndent1"><span class="glyph">●</span>Observational studies (including meta-analyses)</p><p class="bulletIndent1"><span class="glyph">●</span>Ecological studies (these use community-level, epidemiologic data rather than individual-level data)</p><p></p><p class="headingAnchor" id="H16005453"><span class="h2">Randomized trials</span></p><p class="headingAnchor" id="H1290542"><span class="h3">Suicide deaths</span><span class="headingEndMark"> — </span>Three independent analyses combined data from placebo-controlled efficacy trials of various antidepressants to examine risk of suicide death during antidepressant treatment [<a href="#rid17">17-19</a>]. Each analysis found no evidence for higher or lower risk of suicide death during acute-phase treatment with antidepressants compared with risk during treatment with a placebo.</p><p class="bulletIndent1"><span class="glyph">●</span>A meta-analysis of 342 randomized trials (40,826 patients) found no significant difference in suicide deaths for patients treated with a selective serotonin reuptake inhibitor (SSRI) compared with patients treated with placebo (0.04 versus 0.04 percent) [<a href="#rid18">18</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A meta-analysis of 207 randomized trials (40,028 patients) found no significant difference in suicide deaths for patients treated with an antidepressant compared with patients treated with placebo [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A secondary analysis of 48,277 depressed patients found no significant difference in suicide deaths for patients treated with an SSRI, a non-SSRI antidepressant, or placebo (0.15 versus 0.20 versus 0.10 percent) [<a href="#rid17">17</a>].</p><p></p><p>It should be noted that the data used in these analyses were often overlapping, rather than independent.</p><p class="headingAnchor" id="H22905832"><span class="h3">New onset of suicidal behavior</span><span class="headingEndMark"> — </span>Five re-analyses of data from randomized trials suggested that treatment with antidepressants was associated with an increased risk of nonfatal self-harm (attempt) or preparatory acts, compared with placebo [<a href="#rid18">18,20-23</a>]. The increased risk appeared to reside primarily in patients under the age of 25 years.</p><p class="bulletIndent1"><span class="glyph">●</span>Two meta-analyses (n &gt;40,000 and 36,000 patients) focused on SSRI antidepressants and found that the risk of nonfatal self-harm was 1.6 to 2.3 times higher during the first weeks of SSRI treatment compared with treatment with placebo [<a href="#rid18">18,20</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A meta-analysis (372 trials, n &gt;99,000 patients) found that the relative odds of nonfatal self-harm and preparatory acts varied by age. Compared with the risk during placebo treatment, the risk of nonfatal self-harm and preparatory acts during antidepressant treatment was [<a href="#rid21">21</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>More than twice as high in patients under age 25 years (absolute difference approximately 4 per 1000 patients)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Approximately equal in patients age 25 to 64 years</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Approximately half as high in those age 65 or more years (absolute difference approximately 3 per 1000 patients)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A meta-analysis of 70 trials (n &gt;18,000 patients) compared antidepressants (<a class="drug drug_general" data-topicid="8484" href="/d/drug information/8484.html" rel="external">duloxetine</a>, <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a>, <a class="drug drug_general" data-topicid="9743" href="/d/drug information/9743.html" rel="external">paroxetine</a>, <a class="drug drug_general" data-topicid="9886" href="/d/drug information/9886.html" rel="external">sertraline</a>, or <a class="drug drug_general" data-topicid="10042" href="/d/drug information/10042.html" rel="external">venlafaxine</a>) with placebo on the outcome of suicidality, which included suicide, suicide attempt or preparatory behavior, intentional self-harm, and suicidal ideation [<a href="#rid23">23</a>]. The results indicated that suicidality varied by age:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Among adults (age ≥18 years), suicidality was comparable in patients who received antidepressants and placebo (odds ratio 0.8, 95% CI 0.5-1.3).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Among children and adolescents, antidepressants doubled the risk of suicidality (odds ratio 2.4, 95% CI 1.3-4.3).</p><p></p><p>Given the higher frequency of suicide attempts than suicide deaths, these analyses had adequate statistical power to detect effects of treatment with antidepressants overall or with a commonly used class of drugs (such as SSRIs). It appears that there is no difference in risk of suicide attempts among different classes of antidepressants. (See <a class="local">'Differences among antidepressant classes'</a> below.)</p><p>The analyses did not have adequate power to either detect or exclude even relatively large effects of individual antidepressant drugs. In addition, data from these trials could not be used to examine the effect of antidepressants on reducing baseline nonfatal self-harm or preparatory acts, because patients with such behavior were typically excluded from such trials.</p><p class="headingAnchor" id="H1943180129"><span class="h3">New onset of suicidal ideation</span><span class="headingEndMark"> — </span>Among patients with no suicidal ideation at the start of treatment, antidepressants do not increase the incidence of suicidal ideation:</p><p class="bulletIndent1"><span class="glyph">●</span>A pooled analysis of four randomized trials (n = 1399 patients with unipolar major depression) found that in patients with no suicidal ideation at baseline, new onset of suicidal thoughts was comparable with <a class="drug drug_general" data-topicid="16102" href="/d/drug information/16102.html" rel="external">vilazodone</a> and placebo (9 and 10 percent) [<a href="#rid24">24</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A pooled analysis of three randomized trials (n = 1374 patients with generalized anxiety disorder) found that in patients with no suicidal ideation at baseline, new onset of suicidal thoughts was comparable with <a class="drug drug_general" data-topicid="16102" href="/d/drug information/16102.html" rel="external">vilazodone</a> and placebo (4 and 6 percent) [<a href="#rid24">24</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A pooled analysis of four randomized trials (n = 1603 patients with unipolar major depression) found that in patients with no suicidal ideation at baseline, new onset of suicidal thoughts was comparable with <a class="drug drug_general" data-topicid="90236" href="/d/drug information/90236.html" rel="external">levomilnacipran</a> and placebo (11 and 9 percent) [<a href="#rid25">25</a>].</p><p></p><p class="headingAnchor" id="H22905840"><span class="h3">Reduction of existing suicidal ideation</span><span class="headingEndMark"> — </span>Among patients with suicidal ideation at the start of treatment, antidepressants reduce suicidal thoughts and behavior:</p><p class="bulletIndent1"><span class="glyph">●</span>A meta-analysis of patient level data (37 randomized trials, 8477 adult and geriatric patients with unipolar major depression) compared <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a> (modal dose 20 mg per day) or <a class="drug drug_general" data-topicid="10042" href="/d/drug information/10042.html" rel="external">venlafaxine</a> (modal dose range 75 to 150 mg per day) with placebo [<a href="#rid26">26</a>]. The risk of suicidal thoughts and behavior over 12 weeks decreased more with active treatment than placebo; the effect appeared to be mediated by decreases in depressive symptoms.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An eight-week randomized trial compared <a class="drug drug_general" data-topicid="9743" href="/d/drug information/9743.html" rel="external">paroxetine</a> (mean dose 39 mg per day) with placebo in 173 patients with unipolar major depression and found that suicidal ideation improved more with paroxetine, and the effect was clinically large [<a href="#rid27">27</a>].</p><p></p><p class="headingAnchor" id="H471645847"><span class="h3">Suicidality</span><span class="headingEndMark"> — </span>The composite outcome of suicidality includes suicidal ideation, preparatory act, nonfatal self-harm or attempt, or death. Randomized trials indicate that antidepressants do not increase the risk of suicidality in adults. In a meta-analysis of 32 randomized trials (n &gt;8,000 adults) that compared <a class="drug drug_general" data-topicid="8484" href="/d/drug information/8484.html" rel="external">duloxetine</a>, <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a>, <a class="drug drug_general" data-topicid="9743" href="/d/drug information/9743.html" rel="external">paroxetine</a>, <a class="drug drug_general" data-topicid="9886" href="/d/drug information/9886.html" rel="external">sertraline</a>, or <a class="drug drug_general" data-topicid="10042" href="/d/drug information/10042.html" rel="external">venlafaxine</a> with placebo, suicidality was comparable for active treatment and placebo (odds ratio 0.8, 95% CI 0.5-1.3) [<a href="#rid23">23</a>].</p><p class="headingAnchor" id="H2249150277"><span class="h4">Suicidality and age</span><span class="headingEndMark"> — </span>New onset of suicidality (suicidal ideation, preparatory act, nonfatal self-harm or attempt, or death) was evaluated in separate meta-analyses of randomized trials in adults as well as children and adolescents. Taken together, the findings showed a convincing trend of increasing risk in younger age groups, and decreasing risk in older adults  (<a class="graphic graphic_figure graphicRef63706" href="/d/graphic/63706.html" rel="external">figure 1</a>) [<a href="#rid9">9,13</a>]. The pattern is striking, though in itself does not constitute proof:</p><p class="bulletIndent1"><span class="glyph">●</span>Children and adolescents (odds ratio 2.22, 95% CI 1.40-3.60)</p><p class="bulletIndent1"><span class="glyph">●</span>Age 18 to 24 years (odds ratio 1.55, 0.91-2.70)</p><p class="bulletIndent1"><span class="glyph">●</span>Age 25 to 30 years (odds ratio 1.00, 0.60-1.69)</p><p class="bulletIndent1"><span class="glyph">●</span>Age 31 to 64 years (odds ratio 0.77, 0.60-1.00)</p><p class="bulletIndent1"><span class="glyph">●</span>Age ≥65 years (odds ratio 0.39, 0.18-0.78)</p><p></p><p>Studies of individual drugs show a similar trend of increasing risk with younger age. As an example, a meta-analysis of 61 randomized trials (14,911 adult patients with various psychiatric disorders) found that suicidality did not differ significantly between <a class="drug drug_general" data-topicid="9743" href="/d/drug information/9743.html" rel="external">paroxetine</a> compared with placebo (0.9 versus 1.1 percent of patients) [<a href="#rid28">28</a>]. However, a separate analysis of adults age 18 to 24 years found a nonsignificant, twofold increase in suicidality with paroxetine compared with placebo (2.6 versus 1.3 percent of patients; odds ratio 2.0, 95% CI 0.8-4.8). By contrast, the analysis of adults age 25 to 64 years found a nonsignificant decrease in suicidality with paroxetine compared with placebo (0.8 versus 1.1 percent of patients; odds ratio 0.7, 95% CI 0.5-1.0).</p><p class="headingAnchor" id="H25680582"><span class="h3">Methodologic issues</span><span class="headingEndMark"> — </span>The evidence available for examining whether antidepressants cause suicidality in adults is imperfect [<a href="#rid16">16</a>]. The highest quality of existing evidence consists of meta-analyses of data from secondary analyses of randomized efficacy trials.</p><p>The question about whether antidepressants precipitate suicidality should ideally be answered with placebo-controlled trials specifically designed to address this issue. However, no such trials exist and it would not be feasible to assign depressed patients to a long-term placebo arm. Instead, we must rely upon secondary analyses of trials designed to evaluate clinical efficacy and medical adverse events. Our ability to answer the question with these analyses is restricted by certain factors. First, patients at high risk for suicide attempts are typically excluded from such trials (limiting external validity or generalizability) [<a href="#rid16">16</a>]. Thus, data from such trials are limited in their capacity to detect change in suicidality and, in addition, cannot address the patients about whom we are most concerned. A second limitation of existing trials is that assessments were not designed to identify emergence or worsening of suicidal ideation. Consequently, reanalyses of those data depend on post-hoc classification of measurements intended for a different purpose. Third, although most trials involved patients with depression, some trials involved other psychiatric illnesses, such as anxiety disorders. Fourth, trials were short-term in duration, lasting approximately six to eight weeks.</p><p>Suicide deaths are relatively rare events in randomized trials, and there were typically fewer than 100 completed suicides for all drugs and placebo combined in the meta-analyses. Although the analyses included hundreds of trials and tens of thousands of patients, statistical power to detect differences in suicide mortality rates was modest. Thus, none of the analyses could rule out relatively large (ie, three- or fourfold) increases or decreases in risk of suicide mortality during antidepressant treatment compared with placebo. In addition, randomized trials will most likely never have sufficient statistical power to examine suicide mortality with specific antidepressant drugs.</p><p class="headingAnchor" id="H16005466"><span class="h2">Observational studies</span><span class="headingEndMark"> — </span>Observational (cohort and case-control) studies suggest that treatment of depressed patients with an SSRI is associated with fewer suicide attempts or suicide deaths, compared with no treatment with an antidepressant [<a href="#rid29">29-33</a>]. In addition, symptom severity and the rate of suicide attempts appear to be higher during the time period preceding antidepressant treatment, compared with post-treatment.</p><p class="headingAnchor" id="H25680519"><span class="h3">Suicide death or attempt</span><span class="headingEndMark"> — </span>Many observational studies suggest that antidepressants are not associated with an increased risk of suicidal behavior in adults [<a href="#rid30">30,33,34</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>A retrospective study of an administrative claims database in the United States examined suicide attempts in patients with a new episode of depression who were treated with antidepressants (n &gt;100,000) or were not treated with antidepressants (n &gt;200,000) [<a href="#rid35">35</a>]. After adjusting for the probability (propensity) to receive antidepressants, based upon potential confounding factors such as depression severity, history of suicide attempt, and comorbid general medical and psychiatric diagnoses, the analyses found that suicide attempts were comparable for the treated and untreated groups.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A retrospective study used an administrative claims database to examine the use of antidepressants and the number of suicide attempts that occurred before and after the US Food and Drug Administration (FDA) issued its warnings about a possible increased risk of suicidal ideation and behavior due to antidepressants [<a href="#rid36">36</a>]. The dataset included a cohort of young adults age 18 to 29 years (n = 1.4 million). Psychotropic drug poisonings was used as a proxy for suicide attempts. The study found that in the second year (2006) after the warnings, use of antidepressants declined by 24 percent, whereas psychotropic drug poisonings increased by 34 percent. It is worth noting that psychotropic poisonings may include accidental overdoses as well as suicidality.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A meta-analysis of eight observational studies (n &gt;250,000 depressed patients treated with an SSRI) found that use of an SSRI was associated with a decreased risk of suicide death or attempt, compared with no antidepressant treatment in controls (odds ratio 0.6, 95% CI 0.5-0.7) [<a href="#rid29">29</a>]. The protective effect was larger in patients age 65 years or more (odds ratio 0.5).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Data from multiple health care systems, which studied depressed patients treated with antidepressants (n &gt;70,000 [<a href="#rid30">30</a>], n &gt;110,000 [<a href="#rid32">32</a>], and n &gt;50,000) [<a href="#rid35">35</a>], all found the same pattern: suicide attempts were higher in the month before starting antidepressant medication and declined after starting medication.</p><p></p><p class="headingAnchor" id="H25680618"><span class="h3">Methodologic problems</span><span class="headingEndMark"> — </span>Relative strengths and weaknesses of large observational studies are opposite those of randomized trials. Data from large population-based samples increase statistical power and maximize generalizability. However, nonrandom assignment of treatments introduces bias and threatens internal validity, especially if treatment decisions (such as the decision to prescribe an antidepressant or the choice of specific antidepressant) are influenced by clinical characteristics related to risk of suicidality. As an example, SSRIs are safer in overdose than tricyclic antidepressants, and clinicians may thus be more likely to prescribe SSRIs to patients who present with suicidality.</p><p class="headingAnchor" id="H1290505"><span class="h2">Ecological studies</span><span class="headingEndMark"> — </span>Ecological studies used community-level, epidemiologic data to examine whether variation in rates of antidepressant use (either between areas or over time) were associated with variation in suicide deaths. Most studies found that higher rates of antidepressant use were associated with lower rates of suicide death [<a href="#rid37">37-40</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>A cross-sectional analysis of county-level data from the United States found that use of either an SSRI or other antidepressant (<a class="drug drug_general" data-topicid="9684" href="/d/drug information/9684.html" rel="external">nefazodone</a>, <a class="drug drug_general" data-topicid="9656" href="/d/drug information/9656.html" rel="external">mirtazapine</a>, <a class="drug drug_general" data-topicid="9171" href="/d/drug information/9171.html" rel="external">bupropion</a>, or <a class="drug drug_general" data-topicid="10042" href="/d/drug information/10042.html" rel="external">venlafaxine</a>) were each associated with lower suicide mortality [<a href="#rid37">37</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An increase of antidepressant use by 161 percent over a seven-year period in a district of Sweden was accompanied by a 36 percent decrease in the rate of suicide death [<a href="#rid40">40</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Analyses of time trends prior to the FDA warnings found that increasing rates of antidepressant use in England and Japan were accompanied by declines in suicide mortality [<a href="#rid38">38,39</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a study that examined antidepressant prescribing rates and suicide rates across 29 European countries, increased use of antidepressants was associated with decreased suicides [<a href="#rid41">41</a>].</p><p></p><p>However, other ecological studies have found that antidepressant use was not associated with suicide rates [<a href="#rid42">42</a>].</p><p>These ecological studies cannot determine whether differences in suicide deaths are the direct result of differences in antidepressant use or whether differences in antidepressant use are simply a marker for other “true” causes of lower suicide rates (such as better recognition and treatment of depression).</p><p>Several observational studies have focused upon the effects of FDA safety advisories on antidepressant prescribing and suicidal behavior. These studies have generally found that safety advisories and the accompanying publicity were followed by decreases in rates of depression diagnosis and antidepressant prescribing, especially among adolescents and young adults [<a href="#rid36">36,43-45</a>]. Some studies also found evidence for increased rates of suicide attempts or psychotropic drug poisoning [<a href="#rid36">36,45</a>]. All of this research, however, is more relevant to policy questions regarding safety warnings than to the true causal relationship between starting antidepressant treatment and subsequent suicidal ideation or behavior. Whether or not antidepressant drugs sometimes precipitate suicidal ideation or behavior, policy changes (such as safety warnings) can have both intended and unintended consequences.</p><p class="headingAnchor" id="H1366246"><span class="h2">Differences among antidepressant classes</span><span class="headingEndMark"> — </span>Concern about antidepressants and suicidality were first raised in regard to the SSRI <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a> [<a href="#rid5">5</a>], and the FDA warning about antidepressants and suicidality initially focused upon SSRIs and <a class="drug drug_general" data-topicid="9171" href="/d/drug information/9171.html" rel="external">bupropion</a>, <a class="drug drug_general" data-topicid="9656" href="/d/drug information/9656.html" rel="external">mirtazapine</a>, <a class="drug drug_general" data-topicid="9684" href="/d/drug information/9684.html" rel="external">nefazodone</a>, and <a class="drug drug_general" data-topicid="10042" href="/d/drug information/10042.html" rel="external">venlafaxine</a> [<a href="#rid8">8</a>]. The warning now extends to all antidepressants. Although a few observational studies suggest that some antidepressants are associated with higher rates of suicide deaths and attempts [<a href="#rid46">46,47</a>], most randomized trials and observational studies suggest that there is no difference in risk of suicidality among different classes of antidepressants, including SSRIs, serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants, monoamine oxidase inhibitors, and other antidepressants (bupropion, mirtazapine, and nefazodone) [<a href="#rid6">6,17</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>A meta-analysis of randomized trials found that the risk of nonfatal self-harm was comparable for SSRIs and tricyclic antidepressants [<a href="#rid20">20</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Multiple observational studies from different countries have found that different classes of antidepressants are associated with a comparable risk of suicide attempts and deaths [<a href="#rid48">48-52</a>]. One observational study using electronic health records data found that the risk of self-harm was greater in patients starting treatment with <a class="drug drug_general" data-topicid="9656" href="/d/drug information/9656.html" rel="external">mirtazapine</a>, <a class="drug drug_general" data-topicid="10013" href="/d/drug information/10013.html" rel="external">trazodone</a>, or <a class="drug drug_general" data-topicid="10042" href="/d/drug information/10042.html" rel="external">venlafaxine</a>, compared with patients starting treatment with <a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">citalopram</a> [<a href="#rid46">46</a>]. However, another records-based study, which used propensity scoring to account for observed potential confounders, found that self-harm was comparable across individual drugs as well as drug classes [<a href="#rid35">35</a>].</p><p></p><p>Available evidence is not adequate to determine the risk associated with specific antidepressant drugs. </p><p class="headingAnchor" id="H2132586757"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/116503.html" rel="external">"Society guideline links: Depressive disorders"</a>.)</p><p class="headingAnchor" id="H16005424"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Background</strong> – The US Food and Drug Administration (FDA) issued a warning in 2007 that patients age 18 to 24 years should be informed about the risk of becoming suicidal during initial treatment with any antidepressant drug, that clinicians should monitor patients closely during initial antidepressant treatment, and that depression and other serious psychiatric disorders are themselves associated with an increased risk of suicide. The warning does not advise against the use of antidepressants for approved indications, including depressive and anxiety disorders. </p><p></p><p class="bulletIndent1">The small risk of suicidality in young adults associated with antidepressants needs to be balanced against the clear risk of suicidality associated with depressive syndromes. (See <a class="local">'Background'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evidence</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Overview</strong> – There is no clear evidence that antidepressant treatment of depressed patients increases the risk of suicidality (suicidal ideation, action to prepare for an attempt, attempt or nonfatal self-harm, or death) in adults. Randomized trials suggest that antidepressants do not increase the risk of suicidality; some observational and ecological studies show an association between greater antidepressant use and decreased suicide attempts and suicide deaths. (See <a class="local">'Overview'</a> above and <a class="local">'Suicidality'</a> above and <a class="local">'Observational studies'</a> above and <a class="local">'Ecological studies'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Suicidality and age</strong> – Available evidence strongly suggests an age-specific effect of antidepressants and risk of suicidality. Among young adults (and children and adolescents), onset of suicidality is significantly greater compared with placebo. However, the same evidence shows no detectable effect of antidepressant treatment on suicidality in middle-aged adults, and suggests a protective effect (lower risk of suicidality with antidepressant medication than with placebo) among older adults. (See <a class="local">'Suicidality and age'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Differences among antidepressant classes</strong> – Randomized trials and most observational studies suggest there is no difference in risk of suicidality among different classes of antidepressants, including selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants, monoamine oxidase inhibitors, and other antidepressants. Available evidence is not adequate to determine the risk associated with specific antidepressant drugs. (See <a class="local">'Differences among antidepressant classes'</a> above.)</p><p></p><p class="headingAnchor" id="H737756144"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Gregory Simon, MD, MPH, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Williams JW Jr, Mulrow CD, Chiquette E, et al. A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. Ann Intern Med 2000; 132:743.</a></li><li><a class="nounderline abstract_t">Fournier JC, DeRubeis RJ, Hollon SD, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA 2010; 303:47.</a></li><li><a class="nounderline abstract_t">Gartlehner G, Gaynes BN, Hansen RA, et al. Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians. Ann Intern Med 2008; 149:734.</a></li><li class="breakAll">Antidepressant Use in Children, Adolescents, and Adults http://www.fda.gov/drugs/drugsafety/informationbydrugclass/ucm096273.htm (Accessed on October 05, 2010).</li><li><a class="nounderline abstract_t">Teicher MH, Glod C, Cole JO. Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry 1990; 147:207.</a></li><li><a class="nounderline abstract_t">Beasley CM Jr, Dornseif BE, Bosomworth JC, et al. Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression. BMJ 1991; 303:685.</a></li><li class="breakAll">Reports of Suicidality in Pediatric Patients Being Treated with Antidepressant Medications for Major Depressive Disorder (MDD) October 27, 2003. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm168828.htm (Accessed on October 05, 2010).</li><li class="breakAll">Worsening Depression and Suicidality in Patients Being Treated With Antidepressants. US Food and Drug Administration. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm161696.htm (Accessed on March 22, 2004).</li><li><a class="nounderline abstract_t">Friedman RA, Leon AC. Expanding the black box - depression, antidepressants, and the risk of suicide. N Engl J Med 2007; 356:2343.</a></li><li><a class="nounderline abstract_t">Angst F, Stassen HH, Clayton PJ, Angst J. Mortality of patients with mood disorders: follow-up over 34-38 years. J Affect Disord 2002; 68:167.</a></li><li><a class="nounderline abstract_t">Gilbody S, Bower P, Fletcher J, et al. Collaborative care for depression: a cumulative meta-analysis and review of longer-term outcomes. Arch Intern Med 2006; 166:2314.</a></li><li><a class="nounderline abstract_t">Morrato EH, Libby AM, Orton HD, et al. Frequency of provider contact after FDA advisory on risk of pediatric suicidality with SSRIs. Am J Psychiatry 2008; 165:42.</a></li><li><a class="nounderline abstract_t">Leon AC. The revised warning for antidepressants and suicidality: unveiling the black box of statistical analyses. Am J Psychiatry 2007; 164:1786.</a></li><li><a class="nounderline abstract_t">Wessely S, Kerwin R. Suicide risk and the SSRIs. JAMA 2004; 292:379.</a></li><li><a class="nounderline abstract_t">Posner K, Oquendo MA, Gould M, et al. Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants. Am J Psychiatry 2007; 164:1035.</a></li><li><a class="nounderline abstract_t">Healy D. Lines of evidence on the risks of suicide with selective serotonin reuptake inhibitors. Psychother Psychosom 2003; 72:71.</a></li><li><a class="nounderline abstract_t">Khan A, Khan S, Kolts R, Brown WA. Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports. Am J Psychiatry 2003; 160:790.</a></li><li><a class="nounderline abstract_t">Gunnell D, Saperia J, Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review. BMJ 2005; 330:385.</a></li><li><a class="nounderline abstract_t">Hammad TA, Laughren TP, Racoosin JA. Suicide rates in short-term randomized controlled trials of newer antidepressants. J Clin Psychopharmacol 2006; 26:203.</a></li><li><a class="nounderline abstract_t">Fergusson D, Doucette S, Glass KC, et al. Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. BMJ 2005; 330:396.</a></li><li><a class="nounderline abstract_t">Stone M, Laughren T, Jones ML, et al. Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ 2009; 339:b2880.</a></li><li><a class="nounderline abstract_t">Kraus JE, Horrigan JP, Carpenter DJ, et al. Clinical features of patients with treatment-emergent suicidal behavior following initiation of paroxetine therapy. J Affect Disord 2010; 120:40.</a></li><li><a class="nounderline abstract_t">Sharma T, Guski LS, Freund N, Gøtzsche PC. Suicidality and aggression during antidepressant treatment: systematic review and meta-analyses based on clinical study reports. BMJ 2016; 352:i65.</a></li><li><a class="nounderline abstract_t">Thase ME, Edwards J, Durgam S, et al. Effects of vilazodone on suicidal ideation and behavior in adults with major depressive disorder or generalized anxiety disorder: post-hoc analysis of randomized, double-blind, placebo-controlled trials. Int Clin Psychopharmacol 2017; 32:281.</a></li><li><a class="nounderline abstract_t">Thase ME, Gommoll C, Chen C, et al. Measures of suicidality in phase 3 clinical trials of levomilnacipran ER in adults with major depressive disorder. CNS Spectr 2017; 22:475.</a></li><li><a class="nounderline abstract_t">Gibbons RD, Brown CH, Hur K, et al. Suicidal thoughts and behavior with antidepressant treatment: reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine. Arch Gen Psychiatry 2012; 69:580.</a></li><li><a class="nounderline abstract_t">Fournier JC, DeRubeis RJ, Hollon SD, et al. Differential change in specific depressive symptoms during antidepressant medication or cognitive therapy. Behav Res Ther 2013; 51:392.</a></li><li><a class="nounderline abstract_t">Carpenter DJ, Fong R, Kraus JE, et al. Meta-analysis of efficacy and treatment-emergent suicidality in adults by psychiatric indication and age subgroup following initiation of paroxetine therapy: a complete set of randomized placebo-controlled trials. J Clin Psychiatry 2011; 72:1503.</a></li><li><a class="nounderline abstract_t">Barbui C, Esposito E, Cipriani A. Selective serotonin reuptake inhibitors and risk of suicide: a systematic review of observational studies. CMAJ 2009; 180:291.</a></li><li><a class="nounderline abstract_t">Simon GE, Savarino J. Suicide attempts among patients starting depression treatment with medications or psychotherapy. Am J Psychiatry 2007; 164:1029.</a></li><li><a class="nounderline abstract_t">Simon GE, Savarino J, Operskalski B, Wang PS. Suicide risk during antidepressant treatment. Am J Psychiatry 2006; 163:41.</a></li><li><a class="nounderline abstract_t">Gibbons RD, Brown CH, Hur K, et al. Relationship between antidepressants and suicide attempts: an analysis of the Veterans Health Administration data sets. Am J Psychiatry 2007; 164:1044.</a></li><li><a class="nounderline abstract_t">Leon AC, Solomon DA, Li C, et al. Antidepressants and risks of suicide and suicide attempts: a 27-year observational study. J Clin Psychiatry 2011; 72:580.</a></li><li><a class="nounderline abstract_t">Cheung K, Aarts N, Noordam R, et al. Antidepressant use and the risk of suicide: a population-based cohort study. J Affect Disord 2015; 174:479.</a></li><li><a class="nounderline abstract_t">Valuck RJ, Libby AM, Anderson HD, et al. Comparison of antidepressant classes and the risk and time course of suicide attempts in adults: propensity matched, retrospective cohort study. Br J Psychiatry 2016; 208:271.</a></li><li><a class="nounderline abstract_t">Lu CY, Zhang F, Lakoma MD, et al. Changes in antidepressant use by young people and suicidal behavior after FDA warnings and media coverage: quasi-experimental study. BMJ 2014; 348:g3596.</a></li><li><a class="nounderline abstract_t">Gibbons RD, Hur K, Bhaumik DK, Mann JJ. The relationship between antidepressant medication use and rate of suicide. Arch Gen Psychiatry 2005; 62:165.</a></li><li><a class="nounderline abstract_t">Morgan OW, Griffiths C, Majeed A. Association between mortality from suicide in England and antidepressant prescribing: an ecological study. BMC Public Health 2004; 4:63.</a></li><li><a class="nounderline abstract_t">Nakagawa A, Grunebaum MF, Ellis SP, et al. Association of suicide and antidepressant prescription rates in Japan, 1999-2003. J Clin Psychiatry 2007; 68:908.</a></li><li><a class="nounderline abstract_t">Henriksson S, Isacsson G. Increased antidepressant use and fewer suicides in Jämtland county, Sweden, after a primary care educational programme on the treatment of depression. Acta Psychiatr Scand 2006; 114:159.</a></li><li><a class="nounderline abstract_t">Gusmão R, Quintão S, McDaid D, et al. Antidepressant Utilization and Suicide in Europe: An Ecological Multi-National Study. PLoS One 2013; 8:e66455.</a></li><li><a class="nounderline abstract_t">Blüml V, Helbich M, Mayr M, et al. Antidepressant sales and regional variations of suicide mortality in Germany. J Psychiatr Res 2017; 87:88.</a></li><li><a class="nounderline abstract_t">Libby AM, Orton HD, Valuck RJ. Persisting decline in depression treatment after FDA warnings. Arch Gen Psychiatry 2009; 66:633.</a></li><li><a class="nounderline abstract_t">Olfson M, Marcus SC, Druss BG. Effects of Food and Drug Administration warnings on antidepressant use in a national sample. Arch Gen Psychiatry 2008; 65:94.</a></li><li><a class="nounderline abstract_t">Katz LY, Kozyrskyj AL, Prior HJ, et al. Effect of regulatory warnings on antidepressant prescription rates, use of health services and outcomes among children, adolescents and young adults. CMAJ 2008; 178:1005.</a></li><li><a class="nounderline abstract_t">Coupland C, Hill T, Morriss R, et al. Antidepressant use and risk of suicide and attempted suicide or self harm in people aged 20 to 64: cohort study using a primary care database. BMJ 2015; 350:h517.</a></li><li><a class="nounderline abstract_t">Wu CS, Liao SC, Tsai YT, et al. Comparative risk of self-harm hospitalization amongst depressive disorder patients using different antidepressants: a population-based cohort study in Taiwan. Psychol Med 2017; 47:81.</a></li><li><a class="nounderline abstract_t">Schneeweiss S, Patrick AR, Solomon DH, et al. Variation in the risk of suicide attempts and completed suicides by antidepressant agent in adults: a propensity score-adjusted analysis of 9 years' data. Arch Gen Psychiatry 2010; 67:497.</a></li><li><a class="nounderline abstract_t">Søndergård L, Lopez AG, Andersen PK, Kessing LV. Continued antidepressant treatment and suicide in patients with depressive disorder. Arch Suicide Res 2007; 11:163.</a></li><li><a class="nounderline abstract_t">Tiihonen J, Lönnqvist J, Wahlbeck K, et al. Antidepressants and the risk of suicide, attempted suicide, and overall mortality in a nationwide cohort. Arch Gen Psychiatry 2006; 63:1358.</a></li><li><a class="nounderline abstract_t">Martinez C, Rietbrock S, Wise L, et al. Antidepressant treatment and the risk of fatal and non-fatal self harm in first episode depression: nested case-control study. BMJ 2005; 330:389.</a></li><li><a class="nounderline abstract_t">Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suicidal behaviors. JAMA 2004; 292:338.</a></li></ol></div><div id="topicVersionRevision">Topic 14672 Version 23.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10787370" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : A systematic review of newer pharmacotherapies for depression in adults: evidence report summary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20051569" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Antidepressant drug effects and depression severity: a patient-level meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19017592" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19017592" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2301661" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Emergence of intense suicidal preoccupation during fluoxetine treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1833012" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1833012" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1833012" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17485726" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Expanding the black box - depression, antidepressants, and the risk of suicide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12063145" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Mortality of patients with mood disorders: follow-up over 34-38 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17130383" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Collaborative care for depression: a cumulative meta-analysis and review of longer-term outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17986680" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Frequency of provider contact after FDA advisory on risk of pediatric suicidality with SSRIs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18056231" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The revised warning for antidepressants and suicidality: unveiling the black box of statistical analyses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15265855" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Suicide risk and the SSRIs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17606655" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12601224" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Lines of evidence on the risks of suicide with selective serotonin reuptake inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12668373" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15718537" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16633153" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Suicide rates in short-term randomized controlled trials of newer antidepressants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15718539" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19671933" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19439363" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Clinical features of patients with treatment-emergent suicidal behavior following initiation of paroxetine therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26819231" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Suicidality and aggression during antidepressant treatment: systematic review and meta-analyses based on clinical study reports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28538024" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Effects of vilazodone on suicidal ideation and behavior in adults with major depressive disorder or generalized anxiety disorder: post-hoc analysis of randomized, double-blind, placebo-controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28521846" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Measures of suicidality in phase 3 clinical trials of levomilnacipran ER in adults with major depressive disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22309973" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Suicidal thoughts and behavior with antidepressant treatment: reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23644038" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Differential change in specific depressive symptoms during antidepressant medication or cognitive therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21367354" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Meta-analysis of efficacy and treatment-emergent suicidality in adults by psychiatric indication and age subgroup following initiation of paroxetine therapy: a complete set of randomized placebo-controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19188627" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Selective serotonin reuptake inhibitors and risk of suicide: a systematic review of observational studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17606654" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Suicide attempts among patients starting depression treatment with medications or psychotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16390887" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Suicide risk during antidepressant treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17606656" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Relationship between antidepressants and suicide attempts: an analysis of the Veterans Health Administration data sets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21658345" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Antidepressants and risks of suicide and suicide attempts: a 27-year observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25553409" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Antidepressant use and the risk of suicide: a population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26635328" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Comparison of antidepressant classes and the risk and time course of suicide attempts in adults: propensity matched, retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24942789" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Changes in antidepressant use by young people and suicidal behavior after FDA warnings and media coverage: quasi-experimental study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15699293" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The relationship between antidepressant medication use and rate of suicide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15613234" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Association between mortality from suicide in England and antidepressant prescribing: an ecological study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17592916" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Association of suicide and antidepressant prescription rates in Japan, 1999-2003.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16889586" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Increased antidepressant use and fewer suicides in Jämtland county, Sweden, after a primary care educational programme on the treatment of depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23840475" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Antidepressant Utilization and Suicide in Europe: An Ecological Multi-National Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28024215" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Antidepressant sales and regional variations of suicide mortality in Germany.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19487628" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Persisting decline in depression treatment after FDA warnings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18180433" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Effects of Food and Drug Administration warnings on antidepressant use in a national sample.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18390943" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Effect of regulatory warnings on antidepressant prescription rates, use of health services and outcomes among children, adolescents and young adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25693810" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Antidepressant use and risk of suicide and attempted suicide or self harm in people aged 20 to 64: cohort study using a primary care database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27659718" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Comparative risk of self-harm hospitalization amongst depressive disorder patients using different antidepressants: a population-based cohort study in Taiwan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20439831" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Variation in the risk of suicide attempts and completed suicides by antidepressant agent in adults: a propensity score-adjusted analysis of 9 years' data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17453694" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Continued antidepressant treatment and suicide in patients with depressive disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17146010" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Antidepressants and the risk of suicide, attempted suicide, and overall mortality in a nationwide cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15718538" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Antidepressant treatment and the risk of fatal and non-fatal self harm in first episode depression: nested case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15265848" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Antidepressants and the risk of suicidal behaviors.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
